https://www.biopharmadive.com/news/regeneron-factor-xi-blood-thinner-study-results-plans/736022/
The company is planning a “broad Phase 3 program” for two anticoagulants after they outperformed marketed medicines in a pair of mid-stage trials.
data supportbig betsaysstudynew
https://www.biopharmadive.com/news/fdas-rapid-review-pace-nets-an-early-approval-for-alnylams-second-drug/567754/
Givosiran, which will be sold as Givlaari, is the second RNAi therapeutic cleared by the agency after Alnylam's Onpattro.
fdarapidreviewpacenets
https://www.genezen.com/insights/balancing-biopharmas-pressing-priorities/
With intense pressure placed upon the biopharmaceutical industry to rapidly develop and produce COVID-19 vaccines, diagnostics and therapeutics, it is...
supply chainbalancingbiopharmapriorities
https://www.biopharmadive.com/news/viking-obesity-drug-phase-1-data-ozempic/646162/
The biotech is working on a dual-acting weight loss treatment that could compete with medicines from Novo Nordisk, Eli Lilly and others.
drug developmentearly studyvikingjoinsobesity
https://www.morganstanley.com/insights/articles/biopharma-industry-outlook-2025
Discover the factors that could improve investor confidence on the biopharma sector, including more clarity on drug pricing, interest rate cuts and M&A...
industry outlookbiopharmatrendssignalingrebound
https://www.biopharmadive.com/trendline/drug-commercialization-marketing/393/?utm_source=BP&utm_medium=Library&utm_campaign=Evaluate
biopharma divecommercialization
https://www.evaluate.com/webinar/biopharma-dealmaking-emerging-modalities/
Nov 21, 2025 - Discover what’s next in biopharma innovation. Join our webinar for insights into dealmaking trends, emerging modalities, and technologies shaping the future...
webinarbiopharmadealmakingampemerging
https://www.kbibiopharma.com/capabilities/services/microbial-cell-line-development-cld
KBI's Microbial CLD has the advantages of development speed, low cost & scalability.
microbialcelllinedevelopmentkbi
https://www.statnews.com/2025/10/24/pharma-biotech-innovation-stat-summit/
Oct 28, 2025 - The STAT Summit in Boston made clear the drug industry confronts an era of innovation in the shadow of concerns about public trust and pricing.
biopharmagatheringexecutivesfacemoment
https://www.biopharmadive.com/news/novo-nordisk-rybelsus-fda-approval-first-line-diabetes/640376/
The approval could help Rybelsus compete with oral drugs marketed by Eli Lilly, Merck & Co. and others.
novo nordiskfda approvalfirst linediabetespill
https://www.greatplacetowork.co.uk/resources/tackling-the-hidden-pandemic-in-biotech-pharma
The UK’s Best Workplaces are creating work environments that effectively mitigate the risks of burnout and chronic stress faced by employees in the biotech...
hiddenpandemicbiopharma
https://www.biopharmadive.com/news/lilly-terminate-obesity-trial-bimagrumab-muscle-diabetes/761105/
Lilly’s decision comes as the FDA has indicated potentially higher approval standards for drugs meant to preserve muscle in people taking weight loss...
biopharma divelillystopstrialmuscle
https://www.biopharmadive.com/trendline/alzheimers-disease-drugs-research/572/?utm_source=BP&utm_medium=Library&utm_campaign=BectonDickinson
biopharma divealzheimerdisease
https://www.bioworld.com/media/podcasts/532-bioworld-insider-podcast/play/56-two-ceos-discuss-bracing-for-tariffs-nih-grant-cuts-and-gifting-china-biopharma-leadership-position
Breaking news and analysis of the global biotechnology, pharmaceutical, medical device and medical technology sectors. In-depth coverage of innovation,...
twoceosdiscussbracingtariffs
https://www.azonano.com/article.aspx?ArticleID=6989
Learn which nanocarriers matter now (LNPs, exosomes, polymers) and the key hurdles in biodistribution, safety, CMC, and regulatory translation.
emergingbiopharmasmart
https://www.biopharmadive.com/news/fda-roche-polivy-lymphoma-first-line-approval/648184/
The agency’s decision also converts the biologic drug's approval from accelerated to full, confirming an earlier OK based on tumor responses.
fdaearlierusecommonform
https://www.biopharmadive.com/news/gilead-hiv-lenacapavir-sunlenca-european-approval/630170/
European authorities cleared Gilead’s long-acting shot for patients whose HIV infection is resistant to other drugs. An FDA decision is expected by December.
gileadbreaksfirstapprovalnew
https://www.biopharmadive.com/news/athersys-layoffs-restructuring-stroke-trial/624971/
The stem cell therapy company said the restructuring is meant as a first step toward making it "more attractive" to potential financial and...
biotechlaystaffcost
https://www.biopharmadive.com/news/astrazeneca-gets-immuno-oncology-win-in-a-disease-that-merck-doesnt-rule/557794/
Imfinzi's success in small-cell lung cancer pits it against Roche's Tecentriq, as both are now ahead of Merck's Keytruda.
astrazenecagetsoncologywindisease
https://www.biopharmadive.com/news/eli-lilly-tirzepatide-diabetes-novo-nordisk/596155/
The results are a boost for Lilly's drug, tirzepatide, which is being prepared for regulatory submissions later this year. But long-term heart data...
lillysaysdiabetesshotrival
https://www.biopharmadive.com/news/novo-glp1-alzheimers-trials-evoke/806256/
The studies offer perhaps the most concrete rebuttal yet to an idea that GLP-1 drugs, which have profound benefits on weight loss and heart health, might also...
novoglpmissesgoalclosely
https://www.biopharmadive.com/news/unitedhealth-adds-scott-gottlieb-board-of-directors/805924/
The company declined to comment on Gottlieb’s appointment, which comes as it works to improve its relationship with federal regulators.
unitedhealthaddsformerfdacommissioner
https://www.biopharmadive.com/news/pfizer-duchenne-gene-therapy-phase-3-sarepta/592936/
Sarepta, though, may try to seek accelerated approval using Phase 2 data that's due imminently, along with results from another, smaller trial.
late stagepfizerbeatssareptastart
https://www.biopharmaglobal.com/the-benefits-of-working-with-biopharma-global-white-paper/
Dec 6, 2022 - Download our white paper to learn more about the benefits of working with BioPharma Global.
white paperbenefitsworkingbiopharmaglobal
https://www.biopharmadive.com/news/leukemia-rivals-try-to-stay-ahead-as-merck-lilly-chase/568737/
Merck's surprise buyout of ArQule will heat up competition in a class of cancer drugs that includes AbbVie and J&J's Imbruvica and...
leukemiarivalstrystayahead
https://fpcm.es/directorio-de-empresas/allinky-biopharma/
May 20, 2024 - Allinky Biopharma descubre y desarrolla fármacos para tratar patologías relacionadas con inflamación crónica, envejecimiento celular y cáncer.
biopharmaparquedemadrid
https://www.biopharmadive.com/news/novavax-covid-vaccine-fda-advisers-vote-recommend/625050/
Outside experts debated the shot's safety profile and its efficacy versus the omicron variant but ultimately supported the vaccine, which is made...
fdaadvisersbacknovavaxcovid
https://www.tracelink.com/resources/resource-center/eu-biopharma-company-chooses-tracelink-for-o2c-digitalisation
A biopharma manufacturing company serving 40 countries chose TraceLink MINT to rapidly and affordably integrate its 3PL and 4PL partners.
eubiopharmacompanychoosesdigitalization
https://www.biopharmadive.com/news/merck-verona-ohtuvayre-patent-protection-polymorph/752795/
The main patent for Ohtuvayre, the COPD drug at the heart of Verona’s $10 billion sale, expired in 2020. For Merck to make good on the deal, other secondary...
veronadealmerckwagersstrength
https://www.biopharmadive.com/news/fda-advisory-committee-coronavirus-vaccine-kids/601691/
An advisory panel could not reach consensus on how long or large trials in young children should be. Some experts argued falling infection rates might mean...
trialsprogressfdaweighscovid
https://www.biopharmadive.com/news/pfizer-not-for-profit-sale-lower-income-countries-accord/624387/
The pharma has been criticized for not doing enough to make its COVID-19 vaccine and pill available globally. The new initiative commits Pfizer to supplying...
pfizerpledgesprofitsalemedicines
https://www.pharmaceuticalprocessingworld.com/advancing-pressure-protection-in-biopharma-how-integrated-bypass-technology-elevates-single-use-pump-design/
Oct 1, 2025 - by Michael Irving, Xylem In pharmaceutical and biopharmaceutical manufacturing, there is zero margin for error when it comes to process integrity and operator...
pressureprotectionbiopharmaintegratedbypass
https://www.bioprocessintl.com/facilities-capacity/building-a-sustainable-biotech-from-both-the-top-and-bottom-
May 30, 2025 - Discover how biopharma companies are collaborating on sustainability initiatives, including Simtra's comprehensive ESG programs and renewable energy commitments
industry leadersenvironmental impactsustainabilitybiopharmadiscuss
https://www.biopharmadive.com/news/merck-blackstone-adc-royalty-deal-sac-tmt/804597/
The deal hands Blackstone a piece of the potential future sales of an antibody-drug conjugate that could soon challenge marketed medicines from AstraZeneca and...
blackstonepaysmerckbuyadc
https://www.biopharmadive.com/news/biontech-oncoc4-ctla4-cancer-immunotherapy-deal/645440/
The COVID-19 vaccine maker is paying $200 million to secure rights to an experimental CTLA-4 inhibitor that privately held OncoC4 designed to have fewer side...
flushcashbiontechbuysimmunotherapy
https://aijourn.com/how-ai-is-turning-lab-equipment-scheduling-into-mission-critical-infrastructure-for-biopharma/
Nov 28, 2025 - In every biopharma company today, the same question appears in two very different forms:
lab equipmentmission criticalaiturningscheduling
https://www.biopharmadive.com/news/emma-walmsley-retire-gsk-ceo-luke-miels/761344/
Walmsley, who helped push GSK to focus more exclusively on specialty medicines and oncology, will be succeeded by commercial head Luke Miels on Jan. 1.
emmabigfirstfemaleceo
https://events.endpts.com/womeninbio24
<p>Each year, Endpoints recognizes and honors women leaders in the biopharma industry — key figures in the industry who are blazing a trail and pushing...
womenbiopharma
https://www.biopharmadive.com/news/cbo-estimate-pelosi-drug-plan-369b-savings-reduce-research/564962/
Pharma would respond to Pelosi's proposal by raising list prices, keeping some drugs off foreign markets, and cutting R&D spending, according...
pelosidrugplanwouldsave
https://www.kbibiopharma.com/careers
Job listings for KBI Biopharma's facilities: Durham, Research Triangle Park, and Patriot Park (NC), Boulder and Louisville (CO), and Geneva, Switzerland.
careerskbibiopharma
https://www.biocentury.com/analysis/discovery-and-translation
Comprehensive biopharma research and drug discovery intelligence. Preclinical insights, company profiles, and innovation research. BioCentury’s preclinical...
research hubbiopharmadiscoveryamptranslation
https://endpoints.news/biopharma-returns-to-mc4r-for-drugs-targeting-genetic-obesity-as-well-as-appetite-loss/
Aug 28, 2025 - Biotech companies and Pfizer are developing drugs targeting the MC4R pathway for weight control. Rhythm's Imcivree leads the market, while others eye both...
biopharmareturnsdrugstargetinggenetic
https://www.bms.com/it
Per saperne di più su Bristol Myers Squibb e sulla nostra Mission di scoprire, sviluppare e rendere disponibili farmaci innovativi ai pazienti che combattono...
bristol myers squibbaziendabiopharma
https://www.biopharmadive.com/news/pfizer-covid-pill-antiviral-hospitalization/609554/
The drugmaker, which on Oct. 29 won FDA clearance of its vaccine in younger children, plans to quickly ask the agency for emergency authorization of the drug...
pfizerpillcovidshowsdramatic
https://www.biopharmadive.com/news/therapeutics-md-mayne-licensing-drug-deal/637981/
After a private equity takeover unraveled this summer, the women’s health company is selling its drug portfolio to Mayne Pharma in a $153 million deal.
drugsfailedbuyout
https://fprimecapital.com/company/comanche-biopharma/
Jun 11, 2025 - Comanche Biopharma is a maternal and fetal medicine biopharmaceutical company working to lower the risks of pregnancy and premature births worldwide. We are...
comanchebiopharmafprimecapital
https://www.adaptivebiotech.com/mrd-biopharma-services/
Oct 31, 2025 - clonoSEQ assay technology for Biopharma clinical trials provides standardized, validated, sensitive, and specific MRD testing for lymphoid malignancies.
mrdbiopharmaservicesadaptivebiotech
https://partners.weforest.org/sponsor/ucb-biopharma
UCB Biopharma is restoring 7,813.48 ha by growing an estimated 7,602,518 trees
ucbbiopharma
https://www.kornferry.com/insights/featured-topics/resources/how-to-improve-biopharma-launch-success
Biopharmas can strengthen product launches by focusing on organizational effectiveness, which includes decision-making, metric setting, and talent strategy.
improvebiopharmalaunchsuccess
https://www.bioworld.com/media/podcasts/532-bioworld-insider-podcast/play/56-two-ceos-discuss-bracing-for-tariffs-nih-grant-cuts-and-gifting-china-biopharma-leadership-position
Breaking news and analysis of the global biotechnology, pharmaceutical, medical device and medical technology sectors. In-depth coverage of innovation,...
twoceosdiscussbracingtariffs
https://www.statnews.com/2026/01/06/will-artificial-intelligence-designed-drugs-antibodies-revolutionize-biopharma/
Jan 6, 2026 - AI can now design drug-like antibodies, but even biotech executives embracing the new tech say traditional wet lab techniques still have a very important role...
aistartedmakingdruglike
https://www.biopharmadive.com/news/aimmune-fda-approval-palforzia-peanut-allergy/571524/
Aimmune's next challenge will be securing insurance coverage as people allergic to peanuts still have to avoid exposure to the food.
peanut allergyfdadrugfirsttreatment
https://events.endpts.com/jpm
An oasis has emerged in the biopharma money desert as backers look to replenish capital — still, uncertainty remains on whether it's a mirage or the...
endpointsunlockbiopharmanext
https://events.endpts.com/the-endpoints-100-survey-2025
<p>We’ve asked our advisory group in the E100 about how things are shaping up at the FDA and HHS under the new Trump administration and what impact...
endpointssurveybiopharmasaying
https://events.endpts.com/lgbtq24
<p>For the third year, Endpoints is highlighting LGBTQ+ leadership in the biopharma industry in a special report publishing in June. Join the Endpoints...
endpointslgbtqleadersbiopharma
https://www.biopharmadive.com/news/FDA-approve-velsipity-etrasimod-ulcerative-colitis-pfizer/696551/
Acquired with the buyout of Arena Pharmaceuticals, Velsipity enters a competitive market for ulcerative colitis pills.
fda approvalpfizerwinscolitisdrug
https://www.biopharmadive.com/news/fda-lifts-pause-on-novavax-flu-vaccine-trials/732532/
After an investigation, the agency concluded that a case of muscle weakness in one of Novavax’s trials was actually ALS and unrelated to vaccination.
flu vaccinebiopharma divefdaliftspause
https://www.bioworld.com/articles/727991-henlius-in-licenses-anti-il-1rap-antibody-from-u-mab-biopharma?v=preview
Shanghai Henlius Biotech Inc. has entered into an exclusive global license agreement with U-mab Biopharma (Lianyungang) Co. Ltd., securing rights to a...
licensesantiilumab
https://anabolen.org/shop/injecteerbare-steroiden/testosteron-enanthate/
Let op! Geen 12 ml (Dutch Pharma), maar 10 ml (Alpha BioPharma). Afbeelding klopt niet en wordt nog aangepast. Testosteron Enanthate kopen? Alpha BioPharma 250...
testosteron enanthatekopenalphabiopharmamg
https://www.biopharmadive.com/news/pfizer-valneva-lyme-disease-vaccine-phase-3/629200/
The experimental vaccine is the most advanced candidate for the tick-borne disease and, if successful, would be the first to reach the market since withdrawal...
next steplyme diseasepfizervalnevatake
https://www.biopharmadive.com/news/ngm-series-a-raise-column-group-aldafermin/721457/
The Series A round was led by healthcare investor The Column Group, which made the 17-year-old biotechnology company private earlier this year.
ngmprivateraisesredrawnresearch
https://www.prnewswire.com/news-releases/simtra-biopharma-solutions-announces-strategic-purchase-to-expand-us-manufacturing-capacity-for-injectable-medicines-302513753.html?tc=eml_cleartime
/PRNewswire/ -- Simtra BioPharma Solutions, a leading global contract development and manufacturing (CDMO) specializing in injectable medicines, announced...
biopharmasolutionsannouncesstrategicpurchase
https://endpoints.news/special-report-2025-meet-20-women-reshaping-the-future-of-biopharma/
Oct 15, 2025 - A project highlighting women in biopharma has grown since 2019, now honoring over 140 women who've shaped the industry through work on rare diseases, IPOs, AI...
special reportmeetwomenreshapingfuture
https://www.veeva.com/products/veeva-batch-release/
Nov 18, 2025 - Veeva Batch Release software provides real-time visibility into batch status to enable faster, more confident batch release decisions.
veevabatchreleasesoftwarebiopharma
https://www.biopharmadive.com/news/novartis-lutathera-first-line-cancer-study-success/694606/
Novartis has made a large investment in targeted radiotherapies, sparking competition from fellow pharma companies and young biotechs.
first linenovartisdrugsucceedsgut
https://www.mmitnetwork.com/press-releases/norstella-introduces-norstellalinq/
Oct 8, 2024 - NorstellaLinQ integrates 74 billion connected data points, paving the way for breakthroughs in drug development and commercialization.
introducesbiopharmafirstfullyintegrated
https://www.prweb.com/releases/from-science-to-success-syner-g-announces-new-brand--service-model-to-drive-biopharma-innovation-302591255.html
/PRNewswire-PRWeb/ -- Syner-G has unveiled a new brand and service delivery model to accelerate biopharmaceutical product development and commercialization....
sciencesuccessgannouncesnew
https://www.biopharmadive.com/news/fda-fibrogen-advisers-vote-roxadustat-anemia/603458/
Safety worries led to a near-unanimous vote against roxadustat in kidney disease patients, dimming the approval chances of what would be the first pill to...
push backbiopharma divefdaadvisersanemia
https://www.biopharmadive.com/news/harvard-gene-therapy-dyno-sarepta-novartis/577675/
The startup announced collaborations with Novartis and Sarepta, both leading gene therapy makers, that could be worth $2 billion in total.
dynospinsharvardlaboratories
https://www.biopharmadive.com/news/merck-pneumococcal-vaccine-approval-pfizer/603552/
Approval of Merck's shot sets the stage for the two large pharmas to compete for market share with new pneumococcal vaccines that are meant to improve...
mercktakepfizerfdaok
https://www.biopharmadive.com/news/could-novartis-gene-therapy-have-more-than-one-price/555453/
Indication-based pricing may be possible for less severe patients, who would receive a smaller dose. Lower manufacturing costs would lessen the blow to...
gene therapycouldnovartisoneprice
https://www.biopharmadive.com/news/calquence-approval-boosts-astrazeneca-imbruvica-cll/567908/
The new FDA approval expands Calquence's use into a more common blood cancer, although doctors have already been prescribing it for that disease.
okboostsastrazenecachallengebiopharma
https://www.biopharmadive.com/news/roches-oral-sma-drug-scores-in-older-patients/567047/
As Novartis' gene therapy Zolgensma remains under scrutiny, the Swiss rival's risdiplam delivered positive results in older, less severely...
rocheoralsmadrugscores
https://www.biopharmadive.com/news/big-pharma-trump-policy-turning-point-covid/806476/
While Trump’s manufacturing and pricing deals with pharma shape the industry’s future, COVID’s impact still ripples throughout the health landscape.
pharmafacescriticalyears
https://womeninbio23.endpts.com/
Women in Biopharma 2023
womenbiopharma
https://www.biopharmaglobal.com/information-guidance-for-chemistry-manufacturing-and-controls/
Jun 2, 2022 - BioPharma Global’s team of industry experts assist companies and individual clinicians in navigating the IND process as it relates to CMC
informationampguidancechemistrymanufacturing
https://endpoints.news/special-report-meet-20-extraordinary-women-who-are-supercharging-biopharma-rd/
Dec 17, 2021 - Even though many biopharma leaders have come together in recent years to address its gender gap, the consensus is clear: We still have a long way to go....
special reportmeetextraordinarywomensupercharging
https://endpoints.news/our-3rd-annual-uk-biopharma-event-tops-this-week-on-zoom-with-jose-baselga-top-biotech-ceos-and-a-look-at-the-global-financial-scene/
Oct 5, 2020 - The first few years of Pascal Soriot’s reign as CEO of AstraZeneca were tough to watch, at times. Setbacks were more common than breakthroughs, and its...
annualukbiopharmaeventtops
https://medbiollc.com/capabilities/biopharma/
Aug 27, 2024 - Medbio's two-shot molding capabilities provide enhanced functionality and durability to medical device components.
precisionmanufacturingbiopharmallcmedical
https://www.biopharmadive.com/news/halda-series-b-riptac-prostate-cancer/723933/
Technology inspired by work at Yale researcher Craig Crews’ labs will be used to target prostate and breast cancer in early clinical trials.
startupraisesadvancenewtype
https://www.statnews.com/2025/12/17/worst-biopharma-ceo-2025-doug-ingram-sarepta-therapeutics/
Dec 17, 2025 - Ingram has taken on unnecessary risks for Duchenne patients, and hasn't served biotech investors well either.
worstbiopharmaceosareptadoug
https://events.endpts.com/lgbtq25
LGBTQ+ rights, particularly transgender and non-binary rights, are at risk nationwide. But despite the headwinds, there are still many LGBTQ+ individuals...
lgbtqbiopharmaleaders
https://www.biopharmadive.com/news/pfizer-biontech-africa-vaccine-supply-deal/603702/
The companies aim to deliver 100 million doses per year to 55 African countries in an effort to shrink the wide gap between high- and lower-income countries in...
pfizerbiontechinkvaccinesupply
https://www.biopharmadive.com/news/cytokinetics-fda-advisory-committee-vote-heart-failure/638762/
Following years of development, the biotech’s heart failure drug now faces another hurdle in its regulatory path forward, after a group of FDA advisers took...
biopharma diveheartdrugvotedfda
https://www.choosedelaware.com/press-releases/biopharma-company-uvax-bio-chooses-delaware-for-growth/
Jan 8, 2025 - Early-Stage biopharma company Uvax Bio chooses Delaware for expansion and new jobs in its vaccine research, development, and operations.
biopharmacompanychoosesdelaware
https://www.biopharmadive.com/news/astrazeneca-daiichi-breast-cancer-adc-survival-results/727747/
The partners said their antibody-drug conjugate datopotomab deruxtecan didn’t extend survival in a breast cancer study, fueling additional doubts about its...
astrazenecasuccessorfacesquestionslatest
https://medcitynews.com/2025/11/as-healthcare-and-biopharma-companies-embrace-ai-insurance-underwriters-see-risks-and-opportunities/
Dec 8, 2025 - In an interview, Munich Re Specialty Senior Vice President Jim Craig talked about the risk that accompanies innovation and the important role that insurers...
embrace aihealthcarebiopharmacompaniesinsurance
https://www.kbibiopharma.com/capabilities/services/purification-process-analytical-development
KBI Biopharma has a strong reputation for developing purification processes for challenging biomolecules.
purificationprocessanalyticaldevelopmentkbi
https://www.biopharmadive.com/news/merck-pneumococcal-vaccine-fda-approval-capvaxive/719227/
The new vaccine, which Merck will sell as Capvaxive, will compete with Pfizer’s blockbuster Prevnar franchise.
merckwinsfdaokvaccine
https://www.investorbrandnetwork.com/clients/quantum-biopharma-ltd/
Oct 29, 2025 - Disseminated on behalf of Quantum BioPharma Ltd., may include paid advertisements. Investment Considerations Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM)...
quantumbiopharmaltdnasdaqibn
https://endpoints.news/special-report-2022-meet-20-women-blazing-trails-in-biopharma-rd/
Dec 8, 2022 - When you run a special report for a fourth year, it can start feeling a little bit like a ritual. You go through the motions — in our case opening up ...
special reportmeetwomenblazingtrails